|
Priyanka's Biotech Briefing
Distilled Bio uses AI to process and generate content for you. Verify important details using the linked sources.
AI-generated briefing: Elevar secures its first FDA approval, Sobi prepares Gamifant data, and Daewoong reports baseline results from its global IPF trial.
The top 10 stories from Thu Sep 24, 2026 07:07 AM to Fri Sep 25, 2026 07:07 AM
Generated September 25, 2026 at 7:07 AM
|
|
|
#1 Kyverna says long-term data bolster FDA submission for rare autoimmune CAR-T Published 2026-09-24 Kyverna Therapeutics reported positive one-year results for CAR-T treatment in stiff person syndrome, supporting its FDA submission for the rare autoimmune disorder. Covered by: endpoints.news |
#2 Sobi to present clinical data on Gamifant® at Histiocyte Society 2026 in Rotterdam Published 2026-09-24 Sobi will present new clinical data on Gamifant (emapalumab) for primary haemophagocytic lymphohistiocytosis at the Histiocyte Society’s 2026 meeting in Rotterdam. Covered by: prnewswire.com |
#3 Daewoong Pharmaceutical Presents Baseline Characteristics of 104 Patients in Global Phase 2 Trial for IPF Drug Candidate 'Bersiporocin' at ERS 2026 Published 2026-09-24 Daewoong Pharmaceutical reported baseline data from 104 U.S. and South Korean IPF patients in its Phase 2 bersiporocin trial, with top-line results expected in the first half of 2027. Covered by: prnewswire.com |
#4 XtalPi Submits U.S. FDA IND Application for KQTD-126, a Potential First-in-Class, Gut-Restricted Pan-TRK Inhibitor for Chronic Intestinal Pain Published 2026-09-25 XtalPi submitted a U.S. FDA investigational new drug application for KQTD-126, a gut-restricted pan-TRK inhibitor being developed for chronic intestinal pain. Covered by: prnewswire.com |
#5 Network Bio: Building disease-specific AI models with biobank data Published 2026-09-25 Palo Alto-based Network Bio uses patient-derived tissue biobank data to develop disease-specific AI models aimed at tracking disease progression and enabling earlier detection and treatment. Covered by: biocentury.com |
#6 Acadia Alters Phase III Trials To Help Remlifanserin Succeed In Alzheimer’s Psychosis Published 2026-09-24 Acadia modified Phase III trials for remlifanserin, an investigational treatment for Alzheimer’s-related psychosis, affecting approximately 30% of patients. Covered by: insights.citeline.com |
#7 Alexion Aims To Enter Crowded gMG Space With Convenience Advantage For Gefurulimab Published 2026-09-24 AstraZeneca’s Alexion will present 52-week gefurulimab data next week while awaiting FDA review; the drug has Japanese approval and a positive EMA CHMP recommendation. Covered by: insights.citeline.com |
#8 Elevar wins first FDA approval with second-line drug for bile duct cancer Published 2026-09-24 The FDA approved Elevar Therapeutics’ Lyrfigtu as a second-line treatment for certain bile duct cancer patients, marking the company’s first approval. Covered by: endpoints.news |
#9 Endpoints, Study Duration: EMA Sets Out Evidence Bar For Sickle Cell, Thalassemia Drug Approvals Published 2026-09-24 The EMA outlined evidence requirements, including study endpoints and duration, for approving drugs targeting sickle cell disease and thalassemia. Covered by: insights.citeline.com |
#10 Roche secures separate discovery deals with Atavistik, Earendil Published 2026-09-24 Roche has entered separate drug-discovery partnerships with Atavistik Bio and Earendil Labs, extending its recent dealmaking activity. Covered by: endpoints.news, prnewswire.com, biospace.com |
